Marzie Zilaee, Anahita Mansoori, Hosseini Seyed Ahmad, Seyede Marjan Mohaghegh, Maryam Asadi, Razie Hormoznejad
Journal: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 2021;25(4):305-310
PMID: 32436742
OBJECTIVES
The aims of this systematic review and meta-analysis were to evaluate the effectiveness of soy isoflavones on serum levels of total testosterone (TT) and follicle-stimulating hormone (FSH) in women with polycystic ovary syndrome (PCOS).
METHODS
A meta-analysis was performed by searching for relevant randomised controlled trials (RCTs) in several databases. Of the four trials found, the eligibility criteria to evaluate the efficacy of soy isoflavones on serum levels of FSH were met by three trials and of TT by four trials. The Cochrane scale was used to evaluate the risk of bias. Fixed-effects and random-effects models were used to evaluate overall effect. The test (Cochran's test) and the index were used to assess the heterogeneity of RCTs.
RESULTS
Our results showed that soy isoflavones significantly decreased TT (weighted mean difference [WMD] - 0.14; 95% confidence interval [CI] - 0.2, -0.02; = 0.016; = 89%, < 0.001) but had no significant effect on FSH levels (WMD -0.25; 95% CI -0.54, 0.02; = 0.06; = 0%, = 0.85).
CONCLUSION
Although the results of this meta-analysis showed that soy isoflavones in women with PCOS decreased TT and had no significant effect on FSH, better and more valid studies are needed to confirm these results.
Medical:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.